Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

April 24, 2021

Study Completion Date

October 27, 2024

Conditions
Adult T-cell Leukemia/Lymphoma
Interventions
DRUG

Valemetostat Tosylate

Once a day, 200 mg, oral administration

Trial Locations (24)

Unknown

Nagoya City University Hospital, Nagoya

National Cancer Center Hospital East, Kashiwa-shi

Ehime University Hospital, Tōon-shi

Kyushu University Hospital, Fukuoka

National Hospital Organization Kyushu Cancer Center, Fukuoka

Hokkaido University Hospital, Sapporo

Imamura General Hospital, Kagoshima

Kochi Medical School Hospital, Nankoku-shi

Kumamoto University Hospital, Kumamoto

National University Corporation Tohoku University Tohoku University Hospital, Sendai

University of Miyazaki Hospital, Miyazaki

Local Incorporated Administrative Agency Sasebo City General Hospital, Sasebo-shi

Okayama University Hospital, Okayama

University of the Ryukyus Hospital, Nakagami-gun

Osaka International Cancer Institute, Osaka

Kindai University Hospital, Osakasayama-shi

Osaka University Hospital, Suita-shi

Saga University Hospital, Saga

Saitama Medical University International Medical Center, Hidaka-shi

Hamamatsu University Hospital, Hamamatsu

National Cancer Center Hospital, Chuo Ku

IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-Ku

Kagoshima University Hospital, Kagoshima

Nagasaki University Hospital, Nagasaki

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY